Drug intelligence / Profile preview

MG56-VI

Development stage: Unknown
Lead developer: Inmunotek
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Sublingual

Overview

MG56-VI is an investigational allergen immunotherapy developed by INMUNOTEK for the treatment of grass pollen-induced allergic rhinitis and rhinoconjunctivitis. It consists of a polymerized allergoid derived from a 50/50 mixture of Phleum pratense and Dactylis glomerata grass pollen, conjugated with non-oxidized mannan from Saccharomyces cerevisiae using glutaraldehyde. The product is designed to target dendritic cells via the mannan receptor (C-type lectin receptor), promoting allergen uptake and the induction of tolerogenic immune responses. MG56-VI refers to a specific high-dose concentration (5,000 mTU/mL) evaluated in Phase 2 clinical trials for both subcutaneous and sublingual administration.

Other names: mannan-conjugated grass pollen allergoid

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on MG56-VI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG56-VI.

Explore the full profile